Business Wire

TRUFFLE-CAPITAL

Share
Truffle Capital and tecknowlogy Group Unveil the Results of the 15th "Truffle 100" Ranking

On the face of it, the "Truffle 100" 2020 has drawn the curtain on a decade of continuous growth, which has been abruptly halted by the Covid-19 pandemic:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200626005086/en/

  • Several records were set in 2019: cumulative turnover for the sector was €10.8bn, total workforce in the sector stood at 157,000 jobs including 25,000 in R&D. Profitability at 11.1 % is very close to its historical high of 2006-2007. Moreover, buybacks and stock market transactions were sharply higher.

Despite the fact that the solid foundations built over the last decade will be exposed to a brutal shock in 2020, the Truffle 100 clearly shows that the areas in which software publishers have invested the most extensively are those that will be the most vital to withstand the current crisis and support the economic recovery:

  • Thanks to their profit margins, which have returned to previous levels, software publishers have been able to ensure continuous research in crucial areas (in particular, the Cloud and artificial intelligence, which are the two major market trends) to support the transition to teleworking in the economy of tomorrow.

While 62% of software publishers forecast a downturn in 2020, 94% expect a return to growth in 2021.

Commenting on the 15th edition of the "Truffle 100", Bernard-Louis Roques, General Manager and Co-founder of Truffle, declared: "Software is a digital business and software publishers have been among the quickest to adapt to the crisis. In just a few months, Covid-19 brought about a forced acceleration in terms of the company's digital transition, with an irreversible digitalization of uses and organizations. Publishers will play a vital role in the development of the "post-Covid world". Finally, I would like to thank Cédric Ô, the French Secretary of State for the Digital Economy, for agreeing to sponsor the 15th edition of the "Truffle 100", which is more than a just an overview of the past, it is a leading indicator of the future. "

Xavier Negiar, Chairman of the consulting and analysis firm teknowlogy Group which carried out the study and analysis, added:

"As grey as this picture may be, there has been a major trend in this software market to prepare for the end of the crisis. Now is the time to develop programs that are capable of reviving the market. And to achieve this, surely the best approach is to help companies find their own way out of this crisis. "

Cédric Ô, the French Secretary of State for the Digital Economy concluded:

"Software publishers are at the core of all these changes taking place in our societies. They act as stakeholders as well as sentinels and open up new pathways for improvement for the companies they support, the employees who use their solutions and for each and every citizen, which result in significant transformations to life and work. It is this key role that explains the economic strength and resilience of this strategic sector, which is central to France's entrepreneurial fabric and excellence.

The 15th edition of the "Truffle 100", as well as the previous editions, can be viewed on the following website: https://www.truffle100.fr/

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European venture capital company, specializing in life sciences (BioTech and MedTech) and breakthrough technologies in the IT sectors (FinTech and InsurTech). Truffle Capital’s mission is to support the creation and development of young innovative companies capable of becoming tomorrow’s leaders. The company is chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, co-founders and General Managers. Since its creation, Truffle Capital has raised nearly €1.1 billion and has supported over 70 companies in the digital technology and life sciences sectors. In 2019, Truffle Capital announced it had raised nearly €400 million in new institutional funds.

About teknowlogy Group

For more than 45 years, PAC and CXP have been providing visionary and meticulous support, helping stakeholders to grow and adapt in what has become today's IT ecosystem, as well as assisting companies seeking to accelerate their digitalization process. PAC's M&A teams serve the investment fund community both with regard to acquisitions and in the analysis of the coherence of the BP (Business Plan) of their holdings in view of market trends. PAC's teams of analysts also advise ESNs, software publishers and IT service providers in terms of deciphering technological needs to enable them to adapt their strategy to offer solutions and services, owing to their oversight of European and international markets. Thanks to SITSI®, its international platform for real-time monitoring, PAC maintains an up-to-date vision of technologies and markets, and provides its customers with strategic analyses and solution benchmarks for a 360° outlook of the IT market. CXP's Project Consulting teams support TIEs and SMEs in drafting specifications, identifying IT service providers, selecting and implementing solutions adapted to their digital transformation challenges. Thanks to the MyTeknow site - CXP's platform - users now have access to a real-time monitoring of the IT services on offer in France to TIEs and SMEs.

More information: www.truffle.com — Twitter: @trufflecapital

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye